Journal of Asthma最新文献

{"title":"Flavopiridol Inhibits Proliferation and Induces Apoptosis of Rat Airway Smooth Muscle Cells.","authors":"Mi Li, Lijun Xiao, Yang Liu, Chengjiang Tang, Changming Wang, Huiping Qin, Dong Yao, Bo Xiao, Biwen Mo","doi":"10.1080/02770903.2026.2760592","DOIUrl":"https://doi.org/10.1080/02770903.2026.2760592","url":null,"abstract":"<p><p>Cell proliferation and apoptosis are involved in the pathogenesis of many diseases. Abnormal proliferation of airway smooth muscle cells (ASMCs) is a key pathological feature of asthmatic airway remodeling. Flavopiridol is a plant-derived flavonoid that exhibits multifaceted biological activities such as regulating cell proliferation, migration, apoptosis, and autophagy. However, its effect on ASMCs has not been reported yet. Using CCK-8 and EdU assays, we demonstrated that flavopiridol reduced the viability and proliferation of ASMCs. Flow cytometric analysis of the cell cycle revealed an increased proportion of cells in the G2/M phase, accompanied by elevated expression of Cyclin B1 and CDK1, as determined by Western blot. In addition, Western blot showed that flavopiridol downregulated Bcl-2 and upregulated Bax and cleaved caspase-3. Flow cytometry further confirmed the induction of apoptosis in ASMCs. Collectively, our results indicate that flavopiridol suppressed proliferation and triggered apoptosis in rat ASMCs. This in vitro evidence highlights the possible role of flavopiridol in modulating ASMC hyperplasia, a key feature of airway remodeling.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.6,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Serum IL-33 and VEGF Levels in Preschool Children with Recurrent Wheezing.","authors":"Beril Aydın, Burcu Tahire Köksal, Mustafa Agah Tekindal, Özlem Yılmaz Özbek","doi":"10.1080/02770903.2026.2759491","DOIUrl":"https://doi.org/10.1080/02770903.2026.2759491","url":null,"abstract":"<p><strong>Background: </strong>Recurrent wheezing (RW) is a common respiratory condition in preschool children and is associated with an increased risk of subsequent asthma development. Interleukin (IL)-33 and vascular endothelial growth factor (VEGF) are involved in airway inflammation and remodeling, but their role in preschool RW remains unclear. We aimed to evaluate serum IL-33 and VEGF levels and investigate their diagnostic and prognostic value in children with RW.</p><p><strong>Methods: </strong>A total of 132 children were enrolled, including 83 children with RW and 49 healthy controls. Serum IL-33 and VEGF levels were measured by enzyme-linked immunosorbent assay. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis. Children with RW were re-evaluated after three years for asthma development.</p><p><strong>Results: </strong>Serum IL-33 and VEGF levels were significantly higher in children with RW than in controls (both p < 0.001). ROC analysis showed good discriminatory performance for IL-33 (AUC: 0.763, 95% CI: 0.679-0.839) and VEGF (AUC: 0.794, 95% CI: 0.714-0.872). During follow-up, 54 of 83 children (65.1%) developed asthma. Multivariable logistic regression identified elevated VEGF levels, food allergy, and a family history of asthma as independent predictors of asthma development. Each 10 pg/mL increase in VEGF was associated with a 19% increase in asthma risk (adjusted OR: 1.19, 95% CI: 1.05-1.35; p = 0.006).</p><p><strong>Conclusions: </strong>Serum IL-33 and VEGF levels are elevated in preschool children with RW. Elevated VEGF levels independently predict subsequent asthma development, suggesting that VEGF may serve as a non-invasive biomarker for identifying children at increased risk of future asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.6,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classifying Physician-Diagnosed Childhood Asthma Status Using Explainable Machine Learning: NHANES 2007-2016.","authors":"Yuting Zheng","doi":"10.1080/02770903.2026.2759494","DOIUrl":"https://doi.org/10.1080/02770903.2026.2759494","url":null,"abstract":"<p><strong>Objective: </strong>To develop and internally evaluate explainable machine-learning classifiers for physician-diagnosed childhood asthma status and assess the incremental value of five complete-blood-count (CBC)-derived inflammatory indices beyond gender, race, age, family history of asthma, poverty income ratio (PIR), and body mass index (BMI).</p><p><strong>Methods: </strong>NHANES 2007-2016 data from 6,437 children aged 2-14 years were split into training (n = 4,505) and held-out test (n = 1,932) sets. Six machine-learning algorithms were compared using PR-AUC as the primary selection metric. Calibration and the classification threshold were derived from training out-of-fold predictions. The final model was evaluated in the held-out test set. KernelSHAP assessed feature contributions, and repeated nested cross-validation evaluated the incremental value of the five CBC-derived indices.</p><p><strong>Results: </strong>Among 6,437 children, 784 (12.2%) had physician-diagnosed asthma. SVM achieved the highest mean PR-AUC (0.294) during training-set repeated cross-validation and ranked first in all 10 repeats. In the held-out test set, ROC-AUC was 0.743 (95% CI, 0.708-0.778) and PR-AUC was 0.312 (95% CI, 0.268-0.370). At the training-derived threshold of 0.081, sensitivity was 0.672, specificity 0.740, and Brier score 0.097. Family history of asthma had the largest mean absolute SHAP value (0.089). Adding the five CBC-derived indices changed mean PR-AUC from 0.2944 to 0.2956 (paired difference +0.0012; SD 0.0049).</p><p><strong>Conclusion: </strong>The SVM showed moderate discrimination for physician-diagnosed childhood asthma status. CBC-derived inflammatory indices provided no clear incremental improvement beyond gender, race, age, family history, PIR, and BMI. External validation is required before clinical use.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-20"},"PeriodicalIF":1.6,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tezepelumab as a Therapeutic Alternative in Allergic Bronchopulmonary Aspergillosis Suboptimally Controlled by Omalizumab.","authors":"Andreina María Mugno-Saba, Stephanie Steixner-Zevallos, María Reyes Pérez-Giménez, Laura Manzanedo-Ortega, Diana Alejandra D'Elia-Torrence","doi":"10.1080/02770903.2026.2759483","DOIUrl":"https://doi.org/10.1080/02770903.2026.2759483","url":null,"abstract":"<p><p>Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity-mediated respiratory disorder complicating severe asthma, where management frequently requires prolonged systemic corticosteroid (SCS) administration. Although anti-IgE blockade with omalizumab is widely utilized as an SCS-sparing biologic, a subset of patients achieves only partial disease control. We present a clinical perspective and case observation of a 52-year-old female with stage III ABPA and persistent SCS dependence who exhibited a suboptimal response over a 5-year course of omalizumab. Following a therapeutic switch to tezepelumab (210 mg subcutaneously every 4 weeks)-a human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP, an upstream epithelial alarmin)-the patient achieved complete clinical, functional, and structural remission within 12 months. Treatment efficacy was objectively confirmed using the EXACTO (10/10 points) and FEOS (100/100 points) validated severe asthma biologic response scales, alongside total SCS withdrawal and resolution of bronchial mucus impaction. Intercepting the type 2 (T2) inflammatory cascade at its origin via anti-TSLP therapy represents a highly compelling strategy for refractory ABPA phenotypes failing downstream targeted biologics.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-5"},"PeriodicalIF":1.6,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usability, educational engagement, and patient-reported outcomes in a mobile asthma intervention.","authors":"Serena Zhang, Xinqing Li, Da Hae Choi, Sheil Desai, Ronit Patel, Rishab Agarwal, Atiq M Ahsan, Samuel Green, Jonathan M Feldman, Marina Reznik, Zhaoyuan Su, Kai Zheng, Sunit P Jariwala","doi":"10.1080/02770903.2026.2751846","DOIUrl":"10.1080/02770903.2026.2751846","url":null,"abstract":"<p><strong>Objective: </strong>Mobile health tools offer scalable strategies for asthma self-management, but relationships between usability, engagement, and clinical outcomes remain unclear. We evaluated whether usability of ASTHMAXcel PRO, a mobile asthma education and self-management application, promotes educational engagement and whether early engagement predicts asthma outcomes.</p><p><strong>Methods: </strong>Adults with asthma on daily controller therapy from three Bronx clinics participated in a 12-month study using ASTHMAXcel PRO in addition to usual care. Usability was assessed using the Questionnaire for User Interface Satisfaction (QUIS). Early engagement was measured during the first two months, with high educational engagement defined as the top quartile of chapters completed. Outcomes included asthma control (Asthma Control Test [ACT]), asthma-related quality of life (mini-Asthma Quality of Life Questionnaire [mini-AQLQ]), and composite asthma-related healthcare utilization. Associations were examined using mixed-effects, interaction, logistic, and mediation analyses adjusted for age, gender, and baseline outcome status.</p><p><strong>Results: </strong>Among 44 participants (mean age 43.75 ± 14.07 years; 84.1% female; 95.5% non-White), higher usability was associated with greater early engagement (OR 2.39 per 1-SD increase, 95% CI 1.28-5.19, <i>p</i> = 0.01). ACT and mini-AQLQ improved over time. However, early engagement was not associated with differential improvements in either outcome. Baseline outcome status was the strongest predictor of longitudinal outcomes, and no mediation effects were observed.</p><p><strong>Conclusions: </strong>In this urban, high-burden cohort, usability predicted early engagement but not clinical benefit. Baseline outcome status remained the strongest predictor of longitudinal outcomes. These findings suggest that digital asthma interventions may require targeted, content-specific engagement strategies beyond usability alone to improve outcomes.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.6,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between three digital peak expiratory flow devices and spirometry in children and adolescents with asthma.","authors":"Paula do Nascimento Maia, Ana Alice Amaral Ibiapina Parente, Maria de Fátima Bazhuni Pombo Sant Anna, Rafaela Baroni Aurilio, Ronir Raggio Luiz, Raquel Tavares Borda Garrido, Clemax Couto Sant Anna","doi":"10.1080/02770903.2026.2696581","DOIUrl":"10.1080/02770903.2026.2696581","url":null,"abstract":"<p><p>Objective: We compared lung function measurements of three digital peak flow meters (DPMs) to those from spirometry pre and post-bronchodilation (BD). Methods: We conducted a cross-sectional analysis in patients with asthma between 6 and 18 years, evaluating three DPMs: Microlife, Piko, and Asthma-1. We assessed the agreement between measurements using paired t-tests, intraclass correlation coefficients (ICCs), Bland–Altman plots, and survival–agreement plots. Results: The ICCs for peak expiratory flow (PEF) were 0.756 (pre-BD) and 0.762 (post-BD). The spirometry mean was 3.63 L/s, and differences were observed for Microlife (−0.13; p = 0.025), Piko (−0.36; p < 0.001), and Asthma-1 (−0.38; p < 0.001); with similar trends in post-BD. The pre-BD spirometric mean was 1.83 L for forced expiratory volume in 1 s (FEV₁), with significant difference for Microlife (−0.14), Piko (−0.21), and Asthma-1 (−0.30) (all p < 0.001). The corresponding pre-BD ICC was 0.762, with similar results observed post-BD. Bland–Altman analysis for PEF revealed pre-BD differences for Microlife (+2 to −3), Piko (+5 to −4), and Asthma-1 (+2 to −3). Post-BD results showed no change for Microlife and Piko. However, for Asthma-1, a difference of +2 to −4 was observed. FEV₁, differences for Microlife ranged from +0.75 to −1.5 (pre-BD) and +0.5 to −1.5 (post-BD) were observed. Piko ranges were +5.5 to −1.5 (pre-BD) and +4.5 to −2.5 (post-BD); Asthma-1 ranges were +0.5 to −1.5 (pre-BD) and +0.25 to −1.75 (post-BD). Similar results were obtained using the survival–agreement. Conclusions: All DPMs showed moderate agreement with spirometry, with the Microlife device demonstrated comparatively greater accuracy.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1602-1610"},"PeriodicalIF":1.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148352048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment of a multimodal respiratory function diagnostic model and its role in the differential diagnosis of bronchial asthma and chronic obstructive pulmonary disease with incomplete reversible airflow limitation.","authors":"Peng Li, Li Sun, Chao Wang, Qingzhen Gao","doi":"10.1080/02770903.2026.2701399","DOIUrl":"10.1080/02770903.2026.2701399","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective diagnostic test aimed to explore a method that can differentiate asthma from COPD with incomplete reversible airflow limitation.</p><p><strong>Methods: </strong>Patients diagnosed with asthma and COPD from June 19, 2024, to November 16, 2025, were enrolled as training samples. Intergroup data were analyzed through discriminant analysis to determine the quantitative diagnostic formula and the discriminant boundary value <i>Z_c</i> that could identify them. A portion of the patients collected in the same way were used as validation samples to verify the accuracy of the model.</p><p><strong>Results: </strong>128 patients with asthma and 142 with COPD were enrolled as training samples. Through discriminant analysis, the quantitative diagnostic formula was <i>Zi</i> = 1.476<i>X</i>₁+0.348<i>X</i>₂-0.269<i>X</i>₃-0.465<i>X</i>₄+0.995<i>X</i>₅+0.046<i>X</i>₆+0.013<i>X</i>₇-4.479 (<i>X</i>₁ = 0 and <i>X</i>₁ = 1 represent the absence or presence of the concave pattern in the F-V, respectively; <i>X</i>₂, <i>X</i>₃ and <i>X</i>₄ represent forced vital capacity, forced expiratory volume in 1s, and peak expiratory flow, as indicators of bronchodilation test, respectively, 0 = negative, 1 = positive; <i>X</i>₅ represents gender, <i>X</i>₅ = 0 indicates female, and <i>X</i>₅ = 1 indicates male; <i>X</i>₆ represents age; <i>X</i>₇ represents smoking index), and <i>Z</i>_c = -0.0687. The accuracy of the quantitative diagnostic formula, validated internally and externally using 121 patients, was 90.40% and 87.60%, respectively.</p><p><strong>Conclusions: </strong>The multimodal respiratory function diagnostic model, utilizing discriminant analysis, can distinguish asthma with incomplete reversible airflow limitation from COPD when the strongest expiratory effort is performed with an extrapolated volume ≤0.10 L.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1670-1679"},"PeriodicalIF":1.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic model construction of mitochondrial-mitophagy related genes and their regulatory network and potential drug discovery in childhood allergic asthma.","authors":"Wei Lei, Rui Qu, Ning Wang","doi":"10.1080/02770903.2026.2696578","DOIUrl":"10.1080/02770903.2026.2696578","url":null,"abstract":"<p><p><b>Objective:</b> Childhood allergic asthma (CAA) is a chronic allergen-driven airway inflammatory disease whose molecular mechanisms and precise diagnostic and therapeutic strategies remain incompletely understood. This study aimed to identify mitochondrial-mitophagy-related genes (MMRGs) with diagnostic and therapeutic potential in CAA.<b>Methods:</b> Public transcriptomic datasets were analyzed using weighted gene co-expression network analysis and multiple machine learning algorithms to identify diagnostic signature genes and construct a CAA diagnostic model. Immune infiltration, competing endogenous RNA network, and drug-gene interaction analyses were subsequently performed. The expression and biological functions of selected genes were further evaluated in an IL-13-stimulated airway epithelial cell model.<b>Results:</b> Fifteen MMRG-related signature genes with diagnostic potential were identified, and the resulting diagnostic model exhibited good predictive performance. Several immune cell subsets, including resting mast cells, and naive B cells, showed altered infiltration in CAA, and their abundances were significantly correlated with signature-gene expression. The constructed ceRNA network indicated complex post-transcriptional regulation of these genes. Drug-gene interaction analysis identified multiple potential therapeutic compounds, with BCL2-related agents being the most abundant. In IL-13-stimulated airway epithelial cells, MRPL43 expression was increased, whereas BCL2 expression was decreased. MRPL43 knockdown significantly restored cell viability and reduced the secretion of pro-inflammatory cytokines.<b>Conclusions:</b> MMRGs are closely associated with the diagnosis, immune microenvironment, and potential therapeutic regulation of CAA. MRPL43 may contribute to airway epithelial inflammation and represents a potential biomarker and therapeutic target for CAA.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1566-1582"},"PeriodicalIF":1.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhaled corticosteroids monotherapy in childhood asthma: Any differential response rate between activated and prodrugs?","authors":"Poly Majumder, Anna Smyrnova, Francine M Ducharme","doi":"10.1080/02770903.2026.2686931","DOIUrl":"10.1080/02770903.2026.2686931","url":null,"abstract":"<p><strong>Objective: </strong>The efficacy of inhaled corticosteroids (ICS) as prodrugs (inactive at delivery) has been compared to activated ICS, in mean changes in lung function and symptoms, with limited evidence on achieving control. We aimed to compare the real-life success rate of two broad ICS types (prodrug and activated) to prevent poor asthma control and exacerbations in children with asthma.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of children aged 1-17 years, initiating a new maintenance ICS monotherapy at low or medium doses. Initiation referred to a new ICS (after ≥2-month washout) or a switch to another ICS type (prodrug or activated). Co-primary outcomes included: unsatisfactory asthma control, measured by the Pharmacoepidemiologic Pediatric Asthma Control Index, and occurrence of ≥1 severe exacerbation, in following 6 months. A propensity score (PS) weight-adjusted binary logistic regression compared outcomes between ICS types, reporting odds ratios [95% confidence intervals].</p><p><strong>Results: </strong>Of 213 participants (56% male, median age: 6.9 years), 194 were incident users and 19, switchers. Most (<i>N</i> = 148) children were prescribed an activated ICS (97.3% fluticasone propionate, 2.7% budesonide) and 65, an ICS prodrug (100% ciclesonide), 61% using low-dose ICS. The PS-adjusted odds of unsatisfactory asthma control were significantly higher in the prodrug than activated ICS groups (adjOR: 2.35 [95% CI: 1.46-3.81]), with no significant group difference in severe exacerbations (adjOR: 0.92 [95% CI: 0.49-1.72]).</p><p><strong>Conclusions: </strong>Compared to activated ICS, children initiating a prodrug were two-fold more likely to display unsatisfactory control, with no significant difference nor equivalence in likelihood of severe exacerbations.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1479-1487"},"PeriodicalIF":1.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Translational models for acute asthma: critical evaluation of in vivo, in vitro, and emerging technologies in drug discovery\".","authors":"Raihana Nilofar A, Rajendran Priyadharsini","doi":"10.1080/02770903.2026.2721179","DOIUrl":"10.1080/02770903.2026.2721179","url":null,"abstract":"<p><strong>Objectives: </strong>To critically evaluate conventional and emerging preclinical methodologies for screening novel asthma therapeutics; to compare their translational relevance; and to propose an integrated framework aimed at improving precision, safety, and phenotype-targeted efficacy in drug development.</p><p><strong>Data sources: </strong>A review of peer-reviewed literature was conducted using PubMed. Sources included studies on enzymatic and receptor-binding assays, <i>in vitro</i> cellular platforms, allergen-induced animal models, and recent innovations such as 3D airway organoids, lung-on-a-chip microfluidics, and omics-guided biomarker discovery.</p><p><strong>Study selections: </strong>Included studies focused on (i) molecular validation of drug targets, (ii) mechanistic and high-throughput screening in cellular systems, (iii) <i>in vivo</i> replication of asthma pathophysiology in animal models, or (iv) technologies enhancing preclinical predictability.</p><p><strong>Results: </strong>Conventional screening assays provide molecular validation but lack complexity. <i>In vitro</i> systems allow mechanistic insight and scalability, yet do not fully reproduce airway interactions. Allergen-induced animal models replicate inflammation and hyperresponsiveness but fail to capture human heterogeneity or acute exacerbations, a major contributor to morbidity and mortality. Acute asthma remains particularly difficult to model, limiting evaluation of therapies aimed at severe attacks. Emerging approaches, including organoids, lung-on-a-chip, and omics-based biomarkers, offer improved physiological relevance, dynamic assessment of inflammatory responses, and greater potential to model acute disease states.</p><p><strong>Conclusions: </strong>Integrating conventional and innovative models may accelerate the development of safer, more effective, and phenotype-specific asthma therapies. Approaches that incorporate both chronic disease and acute exacerbations could reduce steroid resistance, improve emergency care, and enhance translational success across diverse populations.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1451-1467"},"PeriodicalIF":1.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}